Measurement of Oncostatin M, Leukemia Inhibitory Factor, and Interleukin-11 Levels in Serum, Saliva, and Gingival Crevicular Fluid of Patients with Periodontal Diseases

Tuğba Aydın; Alparslan Dilsiz

doi:10.4274/meandros.galenos.2021.50251

Research Article

Year 2021, Volume: 22 Issue: 3, 242 - 251, 30.12.2021

Tuğba Aydın Alparslan Dilsiz

https://doi.org/10.4274/meandros.galenos.2021.50251

Cited By: 1

Abstract

References

1. Kornman KS, Page RC, Tonetti MS. The host response to the microbial challenge in periodontitis: assembling the players. *Periodontol 2000* 1997; 14: 33-53.
2. Hart TC, Kornman KS. Genetic factors in the pathogenesis of periodontitis. *Periodontol 2000* 1997; 14: 202-15.
3. Birkedal-Hansen H. Role of cytokines and inflammatory mediators in tissue destruction. *J Periodontal Res* 1993; 28: 500-10.
4. Sims NA, Walsh NC. GP130 cytokines and bone remodelling in health and disease. *BMB Rep* 2010; 43: 513-23.
5. Rose-John S. Interleukin-6 Family Cytokines. *Cold Spring Harb Perspect Biol* 2018; 10: a028415.
6. Behrmann I, Hermanns HM, Haan C, Kortylewski M, Radtke S, Greiser J, et al. Signalling of interleukin-6 type cytokines via gp130, leukemia inhibitory factor (LIF) receptor and oncostatin M receptor. *Eur Cytokine Netw* 2000; 11: 491-2.
7. Manicourt DH, Poilvache P, Van Egeren A, Devogelaer JP, Lenz ME, Thonar EJ. Synovial fluid levels of tumor necrosis factor alpha and oncostatin M correlate with levels of markers of the degradation of crosslinked collagen and cartilage aggrecan in rheumatoid arthritis but not in osteoarthritis. *Arthritis Rheum* 2000; 43: 281-8.
8. Lin SJ, Chen YL, Kuo MY, Li CL, Lu HK. Measurement of gp130 cytokines oncostatin M and IL-6 in gingival crevicular fluid of patients with chronic periodontitis. *Cytokine* 2005; 30: 160-7.
9. Martin TJ, Romas E, Gillespie MT. Interleukins in the control of osteoclast differentiation. *Crit Rev Eukaryot Gene Expr* 1998; 8: 107-23.
10. Palmqvist P, Persson E, Conaway HH, Lerner UH. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae. *J Immunol* 2002; 169: 3353-62.
11. Richards CD, Langdon C, Deschamps P, Pennica D, Shaughnessy SG. Stimulation of osteoclast differentiation in vitro by mouse oncostatin M, leukaemia inhibitory factor, cardiotrophin-1 and interleukin 6: synergy with dexamethasone. *Cytokine* 2000; 12: 613-21.
12. Yücel OO, Berker E, Gariboğlu S, Otlu H. Interleukin-11, interleukin-1beta, interleukin-12 and the pathogenesis of inflammatory periodontal diseases. *J Clin Periodontol* 2008; 35: 365-70.
13. Hill GR, Cooke KR, Teshima T, Crawford JM, Keith JC Jr, Brinson YS, et al. Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation. *J Clin Invest* 1998; 102: 115-23.
14. Hermann JA, Hall MA, Maini RN, Feldmann M, Brennan FM. Important immunoregulatory role of interleukin-11 in the inflammatory process in rheumatoid arthritis. *Arthritis Rheum* 1998; 41: 1388-97.
15. Ozmeric N. Advances in periodontal disease markers. *Clin Chim Acta* 2004; 343: 1-16.
16. Armitage GC. Development of a classification system for periodontal diseases and conditions. *Ann Periodontol* 1999; 4: 1-6.
17. Kinane DF, Bartold PM. Clinical relevance of the host responses of periodontitis. *Periodontol 2000* 2007; 43: 278-93.
18. Pan W, Wang Q, Chen Q. The cytokine network involved in the host immune response to periodontitis. *Int J Oral Sci* 2019; 11: 30.
19. Silva N, Abusleme L, Bravo D, Dutzan N, Garcia-Sesnich J, Vernal R, et al. Host response mechanisms in periodontal diseases. *J Appl Oral Sci* 2015; 23: 329-55.
20. Lindhe J, Westfelt E, Nyman S, Socransky SS, Haffajee AD. Long-term effect of surgical/non-surgical treatment of periodontal disease. *J Clin Periodontol* 1984; 11: 448-58.
21. van Oosten MA, Mikx FH, Renggli HH. Microbial and clinical measurements of periodontal pockets during sequential periods of non-treatment, mechanical debridement and metronidazole therapy. *J Clin Periodontol* 1987; 14: 197-204.
22. Badersten A, Nilvéus R, Egelberg J. Effect of nonsurgical periodontal therapy. I. Moderately advanced periodontitis. *J Clin Periodontol* 1981; 8: 57-72.
23. Al-Isa M, Alotibi M, Alhashemi H, Althobiani F, Atia A, Baz S. Effect of non-surgical periodontal therapy on the fibrinogen levels in chronic periodontitis patients. *Saudi Dent J* 2019; 31: 188-93.
24. Afacan B, Öztürk VÖ, Paşalı Ç, Bozkurt E, Köse T, Emingil G. Gingival crevicular fluid and salivary HIF-1α, VEGF, and TNF-α levels in periodontal health and disease. *J Periodontol* 2019; 90: 788-97.
25. Furuse N, Takai H, Ogata Y. Effects of Initial Periodontal Therapy on Heat Shock Protein 70 Levels in Gingival Crevicular Fluid from Periodontitis Patients. *J Clin Med* 2020; 9: 3072.
26. Karsiyaka Hendek M, Kisa U, Olgun E. The effect of smoking on gingival crevicular fluid peptidoglycan recognition protein-1 level following initial periodontal therapy in chronic periodontitis. *Oral Dis* 2020; 26: 166-72.
27. Lee A, Ghaname CB, Braun TM, Sugai JV, Teles RP, Loesche WJ, et al. Bacterial and salivary biomarkers predict the gingival inflammatory profile. *J Periodontol* 2012; 83: 79-89.
28. Salminen A, Gursoy UK, Paju S, Hyvärinen K, Mäntylä P, Buhlin K, et al. Salivary biomarkers of bacterial burden, inflammatory response, and tissue destruction in periodontitis. *J Clin Periodontol* 2014; 41: 442-50.
29. Kamma J, Mombelli A, Tsinidou K, Vasdekis V, Giannopoulou C. Cytokines in gingival crevicular fluid of adolescents and young adults. *Oral Microbiol Immunol* 2009; 24: 7-10.
30. Orozco A, Gemmell E, Bickel M, Seymour GJ. Interleukin 18 and periodontal disease. *J Dent Res* 2007; 86: 586-93.
31. Pradeep AR, S TM, Garima G, Raju A. Serum levels of oncostatin M (a gp 130 cytokine): an inflammatory biomarker in periodontal disease. *Biomarkers* 2010; 15: 277-82.
32. Thorat M, Pradeep AR, Garg G. Correlation of levels of oncostatin M cytokine in crevicular fluid and serum in periodontal disease. *Int J Oral Sci* 2010; 2: 198-207.
33. Becerik S, Öztürk VÖ, Atmaca H, Atilla G, Emingil G. Gingival crevicular fluid and plasma acute-phase cytokine levels in different periodontal diseases. *J Periodontol* 2012; 83: 1304-13.
34. Naemura JR, Radka SF. Detection of oncostatin M in human plasma and serum by a sensitive enzyme immunoassay. *Lymphokine Cytokine Res* 1993; 12: 187-90.
35. Sakai A, Ohshima M, Sugano N, Otsuka K, Ito K. Profiling the cytokines in gingival crevicular fluid using a cytokine antibody array. *J Periodontol* 2006; 77: 856-64.
36. Palmqvist P, Lundberg P, Lundgren I, Hänström L, Lerner UH. IL-1beta and TNF-alpha regulate IL-6-type cytokines in gingival fibroblasts. *J Dent Res* 2008; 87: 558-63.
37. Kitaura H, Marahleh A, Ohori F, Noguchi T, Shen WR, Qi J, et al. Osteocyte-Related Cytokines Regulate Osteoclast Formation and Bone Resorption. *Int J Mol Sci* 2020; 21: 5169.
38. Ahlen J, Andersson S, Mukohyama H, Roth C, Bäckman A, Conaway HH, et al. Characterization of the bone-resorptive effect of interleukin-11 in cultured mouse calvarial bones. *Bone* 2002; 31: 242-51.
39. Morinaga Y, Fujita N, Ohishi K, Zhang Y, Tsuruo T. Suppression of interleukin-11-mediated bone resorption by cyclooxygenases inhibitors. *J Cell Physiol* 1998; 175: 247-54.
40. Johnson RB, Wood N, Serio FG. Interleukin-11 and IL-17 and the pathogenesis of periodontal disease. *J Periodontol* 2004; 75: 37-43.
41. Yetkin Ay Z, Sütçü R, Uskun E, Bozkurt FY, Berker E. The impact of the IL-11\:IL-17 ratio on the chronic periodontitis pathogenesis: a preliminary report. *Oral Dis* 2009; 15: 93-9.
42. Thorat Manojkumar S, Pradeep AR, Garg G, Raju A. Gingival crevicular fluid levels of oncostatin M in periodontal conditions. *Cytokine* 2010; 50: 248-52.

Measurement of Oncostatin M, Leukemia Inhibitory Factor, and Interleukin-11 Levels in Serum, Saliva, and Gingival Crevicular Fluid of Patients with Periodontal Diseases

Year 2021, Volume: 22 Issue: 3, 242 - 251, 30.12.2021

Tuğba Aydın Alparslan Dilsiz

https://doi.org/10.4274/meandros.galenos.2021.50251

Cited By: 1

Abstract

Objective: This study aimed to determine oncostatin M (OSM), interleukin-11 (IL11), and leukemia inhibitory factor (LIF) levels in gingival crevicular fluid (GCF), saliva, and serum in periodontally healthy individuals and those with gingivitis (G) and chronic periodontitis (CP) before and after periodontal treatment and to evaluate the relationship between these cytokine levels and clinical periodontal parameters.
Materials and Methods: This study involved 24 patients with healthy (H) periodontal tissues, 24 patients with G, and 24 patients with CP. Initially, GCF, saliva, and serum samples were collected, and clinical periodontal measurements, including the plaque index, gingival index, probing depth, and clinical attachment levels, were recorded. At 8 weeks after the initial periodontal treatment, the abovementioned parameters were recorded in the G and CP groups. Cytokine levels were determined using enzyme-linked immunosorbent assay.
Results: OSM levels in the GCF, saliva, and serum were significantly higher in the CP group (p<0.05) than in other groups. LIF levels in GCF exhibited a significant increase (p<0.05) in the CP group; however, no significant difference was found in the serum and saliva LIF levels among groups (p˃0.05). IL-11 levels were significantly higher in the CP group (p<0.05) than in other groups, but no significant difference was noted in the serum IL-11 levels among the groups (p˃0.05). Similarly, saliva IL-11 levels were significantly higher in the CP group than in the H group (p<0.05), but they did not show significant difference between the CP and G groups (p˃0.05). Comparative analysis of GCF, saliva OSM, and IL-11 levels in the G and CP groups before and after initial periodontal therapy revealed that they are significantly lower in both groups after therapy (p<0.05).
Conclusion: Levels of OSM, LIF, and IL-11 are higher in the G and CP groups, which indicate periodontal tissue destruction. Decreases in IL-11, OSM, and LIF levels after treatment support the idea that initial periodontal therapy can inhibit periodontal tissue destruction.

Keywords

Chronic periodontitis, interleukin-11, leukemia inhibitory factor, oncostatin M, periodontal therapy

References

1. Kornman KS, Page RC, Tonetti MS. The host response to the microbial challenge in periodontitis: assembling the players. *Periodontol 2000* 1997; 14: 33-53.
2. Hart TC, Kornman KS. Genetic factors in the pathogenesis of periodontitis. *Periodontol 2000* 1997; 14: 202-15.
3. Birkedal-Hansen H. Role of cytokines and inflammatory mediators in tissue destruction. *J Periodontal Res* 1993; 28: 500-10.
4. Sims NA, Walsh NC. GP130 cytokines and bone remodelling in health and disease. *BMB Rep* 2010; 43: 513-23.
5. Rose-John S. Interleukin-6 Family Cytokines. *Cold Spring Harb Perspect Biol* 2018; 10: a028415.
6. Behrmann I, Hermanns HM, Haan C, Kortylewski M, Radtke S, Greiser J, et al. Signalling of interleukin-6 type cytokines via gp130, leukemia inhibitory factor (LIF) receptor and oncostatin M receptor. *Eur Cytokine Netw* 2000; 11: 491-2.
7. Manicourt DH, Poilvache P, Van Egeren A, Devogelaer JP, Lenz ME, Thonar EJ. Synovial fluid levels of tumor necrosis factor alpha and oncostatin M correlate with levels of markers of the degradation of crosslinked collagen and cartilage aggrecan in rheumatoid arthritis but not in osteoarthritis. *Arthritis Rheum* 2000; 43: 281-8.
8. Lin SJ, Chen YL, Kuo MY, Li CL, Lu HK. Measurement of gp130 cytokines oncostatin M and IL-6 in gingival crevicular fluid of patients with chronic periodontitis. *Cytokine* 2005; 30: 160-7.
9. Martin TJ, Romas E, Gillespie MT. Interleukins in the control of osteoclast differentiation. *Crit Rev Eukaryot Gene Expr* 1998; 8: 107-23.
10. Palmqvist P, Persson E, Conaway HH, Lerner UH. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae. *J Immunol* 2002; 169: 3353-62.
11. Richards CD, Langdon C, Deschamps P, Pennica D, Shaughnessy SG. Stimulation of osteoclast differentiation in vitro by mouse oncostatin M, leukaemia inhibitory factor, cardiotrophin-1 and interleukin 6: synergy with dexamethasone. *Cytokine* 2000; 12: 613-21.
12. Yücel OO, Berker E, Gariboğlu S, Otlu H. Interleukin-11, interleukin-1beta, interleukin-12 and the pathogenesis of inflammatory periodontal diseases. *J Clin Periodontol* 2008; 35: 365-70.
13. Hill GR, Cooke KR, Teshima T, Crawford JM, Keith JC Jr, Brinson YS, et al. Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation. *J Clin Invest* 1998; 102: 115-23.
14. Hermann JA, Hall MA, Maini RN, Feldmann M, Brennan FM. Important immunoregulatory role of interleukin-11 in the inflammatory process in rheumatoid arthritis. *Arthritis Rheum* 1998; 41: 1388-97.
15. Ozmeric N. Advances in periodontal disease markers. *Clin Chim Acta* 2004; 343: 1-16.
16. Armitage GC. Development of a classification system for periodontal diseases and conditions. *Ann Periodontol* 1999; 4: 1-6.
17. Kinane DF, Bartold PM. Clinical relevance of the host responses of periodontitis. *Periodontol 2000* 2007; 43: 278-93.
18. Pan W, Wang Q, Chen Q. The cytokine network involved in the host immune response to periodontitis. *Int J Oral Sci* 2019; 11: 30.
19. Silva N, Abusleme L, Bravo D, Dutzan N, Garcia-Sesnich J, Vernal R, et al. Host response mechanisms in periodontal diseases. *J Appl Oral Sci* 2015; 23: 329-55.
20. Lindhe J, Westfelt E, Nyman S, Socransky SS, Haffajee AD. Long-term effect of surgical/non-surgical treatment of periodontal disease. *J Clin Periodontol* 1984; 11: 448-58.
21. van Oosten MA, Mikx FH, Renggli HH. Microbial and clinical measurements of periodontal pockets during sequential periods of non-treatment, mechanical debridement and metronidazole therapy. *J Clin Periodontol* 1987; 14: 197-204.
22. Badersten A, Nilvéus R, Egelberg J. Effect of nonsurgical periodontal therapy. I. Moderately advanced periodontitis. *J Clin Periodontol* 1981; 8: 57-72.
23. Al-Isa M, Alotibi M, Alhashemi H, Althobiani F, Atia A, Baz S. Effect of non-surgical periodontal therapy on the fibrinogen levels in chronic periodontitis patients. *Saudi Dent J* 2019; 31: 188-93.
24. Afacan B, Öztürk VÖ, Paşalı Ç, Bozkurt E, Köse T, Emingil G. Gingival crevicular fluid and salivary HIF-1α, VEGF, and TNF-α levels in periodontal health and disease. *J Periodontol* 2019; 90: 788-97.
25. Furuse N, Takai H, Ogata Y. Effects of Initial Periodontal Therapy on Heat Shock Protein 70 Levels in Gingival Crevicular Fluid from Periodontitis Patients. *J Clin Med* 2020; 9: 3072.
26. Karsiyaka Hendek M, Kisa U, Olgun E. The effect of smoking on gingival crevicular fluid peptidoglycan recognition protein-1 level following initial periodontal therapy in chronic periodontitis. *Oral Dis* 2020; 26: 166-72.
27. Lee A, Ghaname CB, Braun TM, Sugai JV, Teles RP, Loesche WJ, et al. Bacterial and salivary biomarkers predict the gingival inflammatory profile. *J Periodontol* 2012; 83: 79-89.
28. Salminen A, Gursoy UK, Paju S, Hyvärinen K, Mäntylä P, Buhlin K, et al. Salivary biomarkers of bacterial burden, inflammatory response, and tissue destruction in periodontitis. *J Clin Periodontol* 2014; 41: 442-50.
29. Kamma J, Mombelli A, Tsinidou K, Vasdekis V, Giannopoulou C. Cytokines in gingival crevicular fluid of adolescents and young adults. *Oral Microbiol Immunol* 2009; 24: 7-10.
30. Orozco A, Gemmell E, Bickel M, Seymour GJ. Interleukin 18 and periodontal disease. *J Dent Res* 2007; 86: 586-93.
31. Pradeep AR, S TM, Garima G, Raju A. Serum levels of oncostatin M (a gp 130 cytokine): an inflammatory biomarker in periodontal disease. *Biomarkers* 2010; 15: 277-82.
32. Thorat M, Pradeep AR, Garg G. Correlation of levels of oncostatin M cytokine in crevicular fluid and serum in periodontal disease. *Int J Oral Sci* 2010; 2: 198-207.
33. Becerik S, Öztürk VÖ, Atmaca H, Atilla G, Emingil G. Gingival crevicular fluid and plasma acute-phase cytokine levels in different periodontal diseases. *J Periodontol* 2012; 83: 1304-13.
34. Naemura JR, Radka SF. Detection of oncostatin M in human plasma and serum by a sensitive enzyme immunoassay. *Lymphokine Cytokine Res* 1993; 12: 187-90.
35. Sakai A, Ohshima M, Sugano N, Otsuka K, Ito K. Profiling the cytokines in gingival crevicular fluid using a cytokine antibody array. *J Periodontol* 2006; 77: 856-64.
36. Palmqvist P, Lundberg P, Lundgren I, Hänström L, Lerner UH. IL-1beta and TNF-alpha regulate IL-6-type cytokines in gingival fibroblasts. *J Dent Res* 2008; 87: 558-63.
37. Kitaura H, Marahleh A, Ohori F, Noguchi T, Shen WR, Qi J, et al. Osteocyte-Related Cytokines Regulate Osteoclast Formation and Bone Resorption. *Int J Mol Sci* 2020; 21: 5169.
38. Ahlen J, Andersson S, Mukohyama H, Roth C, Bäckman A, Conaway HH, et al. Characterization of the bone-resorptive effect of interleukin-11 in cultured mouse calvarial bones. *Bone* 2002; 31: 242-51.
39. Morinaga Y, Fujita N, Ohishi K, Zhang Y, Tsuruo T. Suppression of interleukin-11-mediated bone resorption by cyclooxygenases inhibitors. *J Cell Physiol* 1998; 175: 247-54.
40. Johnson RB, Wood N, Serio FG. Interleukin-11 and IL-17 and the pathogenesis of periodontal disease. *J Periodontol* 2004; 75: 37-43.
41. Yetkin Ay Z, Sütçü R, Uskun E, Bozkurt FY, Berker E. The impact of the IL-11\:IL-17 ratio on the chronic periodontitis pathogenesis: a preliminary report. *Oral Dis* 2009; 15: 93-9.
42. Thorat Manojkumar S, Pradeep AR, Garg G, Raju A. Gingival crevicular fluid levels of oncostatin M in periodontal conditions. *Cytokine* 2010; 50: 248-52.

There are 42 citations in total.

Details

Primary Language	English
Subjects	Dentistry (Other)
Journal Section	Research Article
Authors	Tuğba Aydın Alparslan Dilsiz
Publication Date	December 30, 2021
Published in Issue	Year 2021 Volume: 22 Issue: 3

Cite

EndNote	Aydın T, Dilsiz A (December 1, 2021) Measurement of Oncostatin M, Leukemia Inhibitory Factor, and Interleukin-11 Levels in Serum, Saliva, and Gingival Crevicular Fluid of Patients with Periodontal Diseases. Meandros Medical And Dental Journal 22 3 242–251.

Cited By

Oral and Gingival Crevicular Fluid Biomarkers for Jawbone Turnover Diseases: A Scoping Review

Diagnostics

https://doi.org/10.3390/diagnostics14192184

Article Files

Full Text